These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24881568)

  • 61. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ligands at Free Fatty Acid Receptor 1 (GPR40).
    Hara T
    Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The therapeutic potential of GPR120: a patent review.
    Halder S; Kumar S; Sharma R
    Expert Opin Ther Pat; 2013 Dec; 23(12):1581-90. PubMed ID: 24094095
    [TBL] [Abstract][Full Text] [Related]  

  • 64. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
    Li H; Fang Y; Guo S; Yang Z
    Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
    [No Abstract]   [Full Text] [Related]  

  • 65. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 66. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

  • 67. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
    Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
    Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
    [TBL] [Abstract][Full Text] [Related]  

  • 68. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 70. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.
    Ghislain J; Poitout V
    Nat Rev Endocrinol; 2021 Mar; 17(3):162-175. PubMed ID: 33495605
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?
    Mancini AD; Poitout V
    Trends Endocrinol Metab; 2013 Aug; 24(8):398-407. PubMed ID: 23631851
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
    Dhayal S; Morgan NG
    Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
    Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds.
    Nie X; Chen Z; Pang L; Wang L; Jiang H; Chen Y; Zhang Z; Fu C; Ren B; Zhang J
    Int J Nanomedicine; 2020; 15():10215-10240. PubMed ID: 33364755
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Natural products with potential hypoglycemic activity in T2DM: 2019-2023.
    Fei Z; Xu Y; Zhang G; Liu Y; Li H; Chen L
    Phytochemistry; 2024 Jul; 223():114130. PubMed ID: 38714289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.